Author/Authors :
mojiri forushani, hoda ahvaz jundishapur university of medical sciences - school of pharmacy, physiology research center - pharmacology department, ايران , hemmati, ali asghar ahvaz jundishapur university of medical sciences - school of pharmacy, physiology research center - pharmacology department, ايران , khodadadi, ali ahvaz jundishapur university of medical sciences (ajums) - school of medicine - immunology department, ايران , assarehzadegan, mohammad-ali iran university of medical sciences - school of medicine - immunology department, ايران , rashno, mohammad ahvaz jundishapur university of medical sciences (ajums) - school of medicine - immunology department, ايران
Abstract :
background: pulmonary fibrosis (pf) is among the world’s most prevalent and common respiratory system diseases. several previous studies have revealed the contribution of angiotensin in the pathogenesis of pf; subsequently, angiotensin-converting enzyme inhibitors (aceis) and angiotensin receptor antagonists (ards) have been proposed for the treatment of pulmonary fibrosis using therapeutic approaches. objectives: this study aimed to investigate the anti-fibrotic effect of valsartan as an angiotensin receptor blocker. methods: rats were given a single intratracheal administration of bleomycin (7.5 iu/kg); valsartan (20, 40, 80 mg/kg/day) was administrated to the rats orally, starting seven days before the induction of lung fibrosis and continuing until the end of the study. the control group received a vehicle. results: the rats that received valsartan exhibited decreased hydroxyprolin content and pulmonary index values. pathological examination showed that valsartan could prevent inflammation and fibrotic scarring induced by bleomycin. conclusions: valsartan displayed an anti-fibrotic and protective effect against bleomycin-induced lung fibrosis in an animal model.
Keywords :
valsartan , pulmonary fibrosis , angiotensin , bleomycin
